When the TGA initially set the maximum dose for over-the-counter CBD at 60mg, most companies feared it was too low to prove efficacy. Avecho CEO Paul Gavin explains why the biotech firm was “probably the only company in Australia that was disappointed when it went up to 150mg” and outlines the next steps in the race for registration. Steve Jones reports.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Biotech firm Avecho is close to unveiling the next stage of its CBD drug registration pathway with scientists in the final stages of settling on an indication that will underpin its pivotal phase III clinical trials.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...